Introduction
Cell and gene therapy has moved from a niche corner of biotech to a category with a meaningful and growing number of approved products, and the regulatory affairs function has had to move with it. If you've spent your career in small-molecule pharma or traditional biologics and are considering a move into cell and gene therapy, or you're early in your career and wondering where to specialize, it's worth understanding how this segment of the job market actually differs from the regulatory affairs roles you may already know — not just in subject matter, but in team structure, required background, and what hiring managers are actually screening for.
Why This Segment Looks Different
Cell and gene therapy products don't fit neatly into the regulatory frameworks built around small molecules or even conventional biologics. Autologous cell therapies, allogeneic products, viral vector-based gene therapies, and gene-edited products each carry distinct manufacturing, potency, and long-term follow-up considerations that regulatory affairs professionals have to translate into a coherent submission strategy. In the United States, these products are generally regulated as biologics under a Biologics License Application (BLA), with additional considerations tied to Chemistry, Manufacturing, and Controls (CMC) that are more complex than for most conventional biologics — potency assays and comparability protocols in particular are harder to standardize when the product itself is a living cell population or a patient-specific batch of a viral vector. Regulatory affairs professionals in this space often work more closely with CMC and manufacturing teams than their counterparts in more established modalities, simply because so much of the regulatory risk sits in demonstrating manufacturing consistency for a product type regulators are still building experience with.
What Roles Actually Look Like
Job titles in cell and gene therapy regulatory affairs tend to mirror standard biotech titles — Regulatory Affairs Specialist, Senior Manager, Director — but the day-to-day scope often skews earlier and more strategic than the same title would in a mature pharma organization. Because many cell and gene therapy companies are pre-commercial or have only recently commercialized their first product, regulatory affairs professionals are frequently involved in original BLA and Investigational New Drug (IND) strategy, orphan drug and rare pediatric disease designation applications, and direct interaction with the FDA's Office of Therapeutic Products, rather than managing lifecycle changes on an already-approved product. This means the role can offer faster exposure to high-stakes regulatory strategy than an equivalent title at a large, established pharmaceutical company — but it also means less institutional infrastructure, fewer established templates, and more ambiguity in day-to-day work.
Regulatory CMC roles specifically are in high demand in this space. Because potency, stability, and comparability are such central regulatory questions for cell and gene products, companies are often looking for regulatory professionals who can speak fluently with process development and analytical teams, not just draft submission sections. A regulatory background paired with hands-on manufacturing or quality experience in biologics is a genuinely differentiated combination for these roles.
What Hiring Managers Are Screening For
Direct cell and gene therapy submission experience is valuable but not always required, particularly for mid-level roles — many hiring managers in this space are realistic that the pool of people with direct BLA experience in gene therapy specifically is small. What they're more consistently screening for is a track record with biologics CMC, familiarity with FDA expedited programs (Regenerative Medicine Advanced Therapy designation, Breakthrough Therapy, Priority Review), and comfort operating without well-established internal precedent. Candidates coming from more conventional biologics or vaccines backgrounds who can point to CMC-heavy submission work, rather than only clinical or labeling-focused regulatory work, tend to be more competitive for cell and gene roles than their titles alone might suggest.
Global experience is also increasingly relevant. The European Medicines Agency (EMA) regulates these products under its Advanced Therapy Medicinal Products (ATMP) framework, which has its own distinct requirements, and companies planning simultaneous or near-simultaneous filings in the U.S. and EU value regulatory professionals who understand both systems rather than only the FDA pathway.
Where the Jobs Are
Cell and gene therapy regulatory roles cluster around a mix of company types: dedicated cell and gene therapy biotechs (both pre-commercial and newly commercial), larger pharmaceutical companies that have built or acquired cell and gene therapy divisions, and contract development and manufacturing organizations (CDMOs) that manufacture these products on behalf of sponsors and need regulatory expertise to support client filings. Each of these settings offers a genuinely different day-to-day experience. A CDMO-side regulatory role tends to be more focused on manufacturing-section support across multiple client programs simultaneously, while a sponsor-side role at a dedicated cell and gene biotech is more likely to involve end-to-end submission ownership for a smaller number of programs.
Academic and Hospital-Based Programs
It's worth noting a segment of cell and gene therapy regulatory work that doesn't show up in a typical industry job search: academic medical centers and hospital-affiliated cell therapy programs that manufacture investigational products under their own IND, often for early-phase, physician-sponsored trials. These programs need regulatory affairs professionals who understand Good Manufacturing Practice (GMP) requirements for small-batch, patient-specific products and who can support an IND application without the infrastructure of a fully staffed industry regulatory department. It's a smaller and less visible part of the job market, but it's a genuine path into the field for people coming from a clinical, quality, or academic research background who want cell and gene therapy exposure without first landing an industry role, and time in one of these programs is increasingly viewed by industry hiring managers as legitimate, relevant experience.
How This Segment Is Likely to Keep Evolving
Cell and gene therapy regulatory affairs has already changed noticeably over the past several years, as the FDA and EMA have published more product-class-specific guidance and built more internal review experience with these modalities. That trajectory is likely to continue: as more products reach approval and post-market follow-up data accumulates, expect the level of established precedent to keep increasing, which should gradually reduce — though not eliminate — the ambiguity that currently defines much of the work. Regulatory professionals who build deep expertise now, while the field is still forming its norms, are well positioned to become the internal precedent-setters that newer entrants to the field will eventually be hired to learn from.
It's also worth watching how manufacturing technology shifts affect the regulatory function specifically. As allogeneic ("off-the-shelf") cell therapies mature relative to the autologous, patient-specific model that dominated the field's early years, the regulatory questions shift too — allogeneic products raise different comparability and lot-release considerations, closer in some ways to conventional biologics manufacturing, which may in turn shift what kind of regulatory background hiring managers prioritize.
Skills Worth Building Now
If you're targeting this segment, a few areas of study pay off disproportionately. Understanding potency assay development and comparability protocol design, even at a conceptual level, will make you more credible in interviews than general regulatory affairs knowledge alone. Familiarity with FDA guidance specific to cell and gene therapy — the agency has published a meaningful body of product-class-specific guidance over the past several years — signals genuine interest rather than opportunistic career-switching. And exposure to orphan drug and rare pediatric disease designation processes is valuable because a large share of early cell and gene therapy programs target rare diseases, where these designations meaningfully affect both regulatory strategy and commercial planning.
Building a Case for Yourself Without Direct Experience
If you don't have cell and gene therapy experience on your resume but want to move in that direction, the strongest approach is usually to demonstrate adjacent depth rather than trying to manufacture direct experience you don't have. Highlighting biologics CMC work, any exposure to potency or comparability testing, involvement in expedited program applications, or even coursework or RAPS continuing education focused specifically on advanced therapies can meaningfully strengthen a resume and interview narrative. Framing a transition honestly — explaining why the field interests you and what transferable experience you bring — tends to land better with hiring managers than overstating direct relevance that isn't there. Many hiring managers in this space were themselves hired from adjacent backgrounds a few years ago and are realistic about what a reasonable transition looks like.
Realistic Expectations About the Transition
Moving into cell and gene therapy regulatory affairs from a more conventional pharma or device background is achievable, but it's worth being honest about the adjustment. Precedent is thinner, guidance is still evolving faster than in more mature modalities, and the tolerance for ambiguity required is genuinely higher. Professionals who thrive in this space tend to be comfortable building a regulatory strategy without a clean prior example to model it on, and comfortable having that strategy evolve through iterative agency interaction rather than following an established playbook. If that ambiguity is energizing rather than stressful for you, this segment offers some of the most substantive, strategy-level regulatory work available anywhere in the industry right now. If it's not, there's no shame in that — a huge amount of valuable regulatory affairs work still happens in more established modalities with clearer precedent.
Conclusion
Cell and gene therapy regulatory affairs is a distinct segment of the job market, not simply biologics regulatory work with a different product label. It rewards candidates who bring genuine CMC and manufacturing fluency, comfort with regulatory ambiguity, and — increasingly — familiarity with both FDA and EMA advanced therapy frameworks. For regulatory professionals looking to build a differentiated, strategy-heavy career track, it's one of the more compelling places to specialize; for those who prefer well-established precedent and process, it's fair to recognize that this isn't the right fit, and that's a reasonable thing to know about yourself before you make the move.